Meng Yuan Profile picture
22 Feb, 6 tweets, 4 min read
Recent #SARSCoV2 variants in South Africa (B.1.351) and Brazil (P.1) reduce neutralization of patient and vaccinated sera. Our new study reveals the molecular basis of how major classes of antibodies are extremely sensitive to the key mutations. (1/6) biorxiv.org/content/10.110…
We analyzed 1,593 SARS-CoV-2 antibodies targeting the receptor binding domain (RBD), and found that IGHV3-53/3-66 and IGHV1-2 are the two most frequently elicited antibody families. Strikingly, neutralization of all tested antibodies from these germlines was abolished. (2/6)
Most IGHV3-53/3-66 antibodies are structurally convergent to two binding modes, where K417N or E484K abrogates the binding and neutralization. (3/6)
Likewise, IGHV1-2 antibodies are also structurally convergent to two binding modes, where E484K abrogates the binding and neutralization. (4/6)
In contrast, neutralizing antibodies to the cross-reactive CR3022 and S309 sites are largely unaffected. (5/6)

• • •

Missing some Tweet in this thread? You can try to force a refresh
 

Keep Current with Meng Yuan

Meng Yuan Profile picture

Stay in touch and get notified when new unrolls are available from this author!

Read all threads

This Thread may be Removed Anytime!

PDF

Twitter may remove this content at anytime! Save it as PDF for later use!

Try unrolling a thread yourself!

how to unroll video
  1. Follow @ThreadReaderApp to mention us!

  2. From a Twitter thread mention us with a keyword "unroll"
@threadreaderapp unroll

Practice here first or read more on our help page!

Did Thread Reader help you today?

Support us! We are indie developers!


This site is made by just two indie developers on a laptop doing marketing, support and development! Read more about the story.

Become a Premium Member ($3/month or $30/year) and get exclusive features!

Become Premium

Too expensive? Make a small donation by buying us coffee ($5) or help with server cost ($10)

Donate via Paypal Become our Patreon

Thank you for your support!

Follow Us on Twitter!